Caris launches AI-driven test to predict early and late breast cancer recurrence risk in postmenopausal patients.

Caris Life Sciences has introduced Caris MI Clarity™, an AI-powered prognostic test that assesses both early and late distant recurrence risks for postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer. The test uses AI to analyze routine pathology slides and clinical data, delivering results within three business days, much faster than traditional methods. This innovation helps doctors better personalize treatment by understanding how recurrence risk evolves over time, potentially improving patient outcomes and reducing overtreatment or undertreatment. The test's development involved extensive validation with national clinical trial data, marking a significant advancement in breast cancer risk assessment and management.